Aktis Oncology (AKTS) has drawn investor attention after recent trading swings, with the stock down 4% over the past week and around 17% over the past month, despite year-to-date gains.

The recent 30 day share price return of down 16.8% has cooled earlier gains, even though the 90 day share price return of 12.4% and 6.7% year to date still point to fading, but not fully reversed, momentum for Aktis Oncology around the latest close at $23.89.

If you are weighing Aktis Oncology against other potential opportunities in cancer and radiopharmaceutical research, it may be a good time to broaden your watchlist with 39 healthcare AI stocks

Aktis Oncology has a focused radiopharmaceutical pipeline and a market value of about $1.33b, yet the stock has pulled back sharply in the past month. Does that recent slide leave Aktis Oncology attractively priced today, or is it still punchy?

Preferred Price-to-Book Multiple of 2.6x: Is it justified?

Aktis Oncology currently trades at a P/B of 2.6x, slightly above the US Biotechs industry average of 2.5x, which points to a modest premium to the broader sector while still sitting below the 5.1x peer group average flagged in the data.

The P/B ratio compares the company’s market value to its book value. It is often used for early stage or loss making biotechnology companies where earnings based measures are less informative. For Aktis Oncology, this means investors are paying 2.6 times the accounting value of its net assets at the latest close around $23.89, a level that sits in between sector peers and the wider industry.

That positioning implies the market is willing to pay more than the typical biotech company for Aktis Oncology’s balance sheet, but less than for its closer peer set where valuations average 5.1x book value. If sentiment were to shift closer to that peer average, there is room for the P/B multiple to move. A retracement toward the broader industry level of 2.5x would suggest only a small change compared with where the stock trades today.

Result: Price-to-book of 2.6x (ABOUT RIGHT)

However, Aktis Oncology is still loss making, with net income of $67.071m in the red, and relies on early stage trials, so clinical or funding setbacks could quickly pressure sentiment.

Next Steps

Given the mixed signals around Aktis Oncology, it can help to look past the headlines and review the underlying data directly before forming an opinion. To weigh both the potential upside and areas of concern side by side, start with the 2 key rewards and 3 important warning signs

Looking for more investment ideas beyond Aktis Oncology?

If Aktis Oncology is already on your radar, it makes sense to line up a few other candidates so you are not relying on a single stock or theme.

• Target companies that combine quality with a potential discount by scanning through the 49 high quality undervalued stocks.
• Prioritise resilience and capital protection by focusing on stocks highlighted in the 81 resilient stocks with low risk scores.
• Hunt for future standouts that are not widely followed yet by checking the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.